1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Global Adalimumab Market
4. Executive Summary
5. Voice of Customer
6.
Global Adalimumab Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Type (Adalimumab,
Adalimumab Biosimilar)
6.2.2. By Type of Disease
(Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease,
Ulcerative Colitis)
6.2.3. By Route of
Administration (Parenteral, Others)
6.2.4. By End Users
(Hospitals, Specialty Clinics, Others)
6.2.5. By Distribution
Channel (Hospital Pharmacy, Retail Pharmacy, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3. Market Attractiveness Index
7.
Asia-Pacific Adalimumab Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Type of Disease
7.2.2. By Route of
Administration
7.2.3. By End Users
7.2.4. By Distribution
Channel
7.2.5. By Country
7.3.
Market Attractiveness Index
7.4.
Asia-Pacific: Country Analysis
7.4.1. China Adalimumab
Market Outlook
7.4.1.1.
Market Size & Forecast
7.4.1.1.1.
By Value
7.4.1.2.
Market Share & Forecast
7.4.1.2.1.
By Type of Disease
7.4.1.2.2.
By Route of Administration
7.4.1.2.3.
By End Users
7.4.1.2.4.
By Distribution Channel
7.4.2. India Adalimumab
Market Outlook
7.4.2.1.
Market Size & Forecast
7.4.2.1.1.
By Value
7.4.2.2.
Market Share & Forecast
7.4.2.2.1.
By Type of Disease
7.4.2.2.2.
By Route of Administration
7.4.2.2.3.
By End Users
7.4.2.2.4.
By Distribution Channel
7.4.3. Japan Adalimumab
Market Outlook
7.4.3.1.
Market Size & Forecast
7.4.3.1.1.
By Value
7.4.3.2.
Market Share & Forecast
7.4.3.2.1.
By Type of Disease
7.4.3.2.2.
By Route of Administration
7.4.3.2.3.
By End Users
7.4.3.2.4.
By Distribution Channel
7.4.4. South Korea Adalimumab
Market Outlook
7.4.4.1.
Market Size & Forecast
7.4.4.1.1.
By Value
7.4.4.2.
Market Share & Forecast
7.4.4.2.1.
By Type of Disease
7.4.4.2.2.
By Route of Administration
7.4.4.2.3.
By End Users
7.4.4.2.4.
By Distribution Channel
7.4.5. Singapore Adalimumab
Market Outlook
7.4.5.1.
Market Size & Forecast
7.4.5.1.1.
By Value
7.4.5.2.
Market Share & Forecast
7.4.5.2.1.
By Type of Disease
7.4.5.2.2.
By Route of Administration
7.4.5.2.3.
By End Users
7.4.5.2.4.
By Distribution Channel
7.4.6. Australia Adalimumab
Market Outlook
7.4.6.1.
Market Size & Forecast
7.4.6.1.1.
By Value
7.4.6.2.
Market Share & Forecast
7.4.6.2.1.
By Type of Disease
7.4.6.2.2.
By Route of Administration
7.4.6.2.3.
By End Users
7.4.6.2.4.
By Distribution Channel
8.
Europe Adalimumab Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Type of Disease
8.2.2. By Route of
Administration
8.2.3. By End Users
8.2.4. By Distribution
Channel
8.2.5. By Country
8.3.
Market Attractiveness Index
8.4.
Europe: Country Analysis
8.4.1. France Adalimumab
Market Outlook
8.4.1.1.
Market Size & Forecast
8.4.1.1.1.
By Value
8.4.1.2.
Market Share & Forecast
8.4.1.2.1.
By Type of Disease
8.4.1.2.2.
By Route of Administration
8.4.1.2.3.
By End Users
8.4.1.2.4.
By Distribution Channel
8.4.2. Germany Adalimumab
Market Outlook
8.4.2.1.
Market Size & Forecast
8.4.2.1.1.
By Value
8.4.2.2.
Market Share & Forecast
8.4.2.2.1.
By Type of Disease
8.4.2.2.2.
By Route of Administration
8.4.2.2.3.
By End Users
8.4.2.2.4.
By Distribution Channel
8.4.3. United Kingdom
Adalimumab Market Outlook
8.4.3.1.
Market Size & Forecast
8.4.3.1.1.
By Value
8.4.3.2.
Market Share & Forecast
8.4.3.2.1.
By Type of Disease
8.4.3.2.2.
By Route of Administration
8.4.3.2.3.
By End Users
8.4.3.2.4.
By Distribution Channel
8.4.4. Italy Adalimumab
Market Outlook
8.4.4.1.
Market Size & Forecast
8.4.4.1.1.
By Value
8.4.4.2.
Market Share & Forecast
8.4.4.2.1.
By Type of Disease
8.4.4.2.2.
By Route of Administration
8.4.4.2.3.
By End Users
8.4.4.2.4.
By Distribution Channel
8.4.5. Spain Adalimumab
Market Outlook
8.4.5.1.
Market Size & Forecast
8.4.5.1.1.
By Value
8.4.5.2.
Market Share & Forecast
8.4.5.2.1.
By Type of Disease
8.4.5.2.2.
By Route of Administration
8.4.5.2.3.
By End Users
8.4.5.2.4.
By Distribution Channel
9.
North America Adalimumab Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Type of Disease
9.2.2. By Route of
Administration
9.2.3. By End Users
9.2.4. By Distribution
Channel
9.2.5. By Country
9.3.
Market Attractiveness Index
9.4.
North America: Country Analysis
9.4.1. United States Adalimumab
Market Outlook
9.4.1.1.
Market Size & Forecast
9.4.1.1.1.
By Value
9.4.1.2.
Market Share & Forecast
9.4.1.2.1.
By Type of Disease
9.4.1.2.2.
By Route of Administration
9.4.1.2.3.
By End Users
9.4.1.2.4.
By Distribution Channel
9.4.2. Mexico Adalimumab
Market Outlook
9.4.2.1.
Market Size & Forecast
9.4.2.1.1.
By Value
9.4.2.2.
Market Share & Forecast
9.4.2.2.1.
By Type of Disease
9.4.2.2.2.
By Route of Administration
9.4.2.2.3.
By End Users
9.4.2.2.4.
By Distribution Channel
9.4.3. Canada Adalimumab
Market Outlook
9.4.3.1.
Market Size & Forecast
9.4.3.1.1.
By Value
9.4.3.2.
Market Share & Forecast
9.4.3.2.1.
By Type of Disease
9.4.3.2.2.
By Route of Administration
9.4.3.2.3.
By End Users
9.4.3.2.4.
By Distribution Channel
10.
South America Adalimumab Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Type of Disease
10.2.2. By Route of
Administration
10.2.3. By End Users
10.2.4. By Distribution
Channel
10.2.5. By Country
10.3.
Market Attractiveness Index
10.4.
South America: Country Analysis
10.4.1. Brazil Adalimumab
Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1.
By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1.
By Type of Disease
10.4.1.2.2.
By Route of Administration
10.4.1.2.3.
By End Users
10.4.1.2.4.
By Distribution Channel
10.4.2. Argentina Adalimumab
Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1.
By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1.
By Type of Disease
10.4.2.2.2.
By Route of Administration
10.4.2.2.3.
By End Users
10.4.2.2.4.
By Distribution Channel
10.4.3. Colombia Adalimumab
Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1.
By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1.
By Type of Disease
10.4.3.2.2.
By Route of Administration
10.4.3.2.3.
By End Users
10.4.3.2.4.
By Distribution Channel
11.
Middle East and Africa Adalimumab Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Type of Disease
11.2.2. By Route of
Administration
11.2.3. By End Users
11.2.4. By Distribution
Channel
11.2.5. By Country
11.3.
Market Attractiveness Index
11.4.
MEA: Country Analysis
11.4.1. South Africa
Adalimumab Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1.
By Value
11.4.1.2. Market Share & Forecast
11.4.1.2.1.
By Type of Disease
11.4.1.2.2.
By Route of Administration
11.4.1.2.3.
By End Users
11.4.1.2.4.
By Distribution Channel
11.4.2. Saudi Arabia Adalimumab
Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1.
By Value
11.4.2.2. Market Share & Forecast
11.4.2.2.1.
By Type of Disease
11.4.2.2.2.
By Route of Administration
11.4.2.2.3.
By End Users
11.4.2.2.4.
By Distribution Channel
11.4.3. UAE Adalimumab
Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1.
By Value
11.4.3.2. Market Share & Forecast
11.4.3.2.1.
By Type of Disease
11.4.3.2.2.
By Route of Administration
11.4.3.2.3.
By End Users
11.4.3.2.4.
By Distribution Channel
12.
Market Dynamics
12.1.
Drivers
12.2.
Challenges
13.
Market Trends & Developments
14.
Competitive Landscape
14.1.
Competition Outlook
14.2.
Players Profiled (Leading Companies)
14.2.1.
Abbvie Inc.
14.2.2.
Pfizer Inc.
14.2.3.
Amgen Inc.
14.2.4.
Novartis AG
14.2.5.
Mylan N.V.6
14.2.6.
Samsung Bioepis Co Ltd.
14.2.7.
Boehringer Ingelheim International GmbH
14.2.8.
Merck & Co., Inc.
14.2.9.
Cadila Healthcare Ltd.
14.2.10.
Hetero Healthcare Ltd.
14.2.11.
Bristol-Myers Squibb
14.2.12.
Hoffmann-La Roche Ltd.
14.2.13.
Glenmark Pharmaceuticals
14.2.14.
Torrent Pharmaceuticals Ltd.
15. Strategic Recommendations
In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com